Acrotech Biopharma
1 products tracked · names used in filings: Acrotech Biopharma
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Thu 12 Feb 2026🇺🇸 FDA approval
FDA approves Adquey (difamilast), a new medicine
Acrotech Biopharma; NDA219474; New molecular entity; ointment · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Adquey difamilast | Approved | 2026-02-12 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.